Telaprevir/boceprevir era: from bench to bed and back.


Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have… (More)
DOI: 10.3748/wjg.v18.i43.6183


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.